Fresenius Medical Care AG (ETR:FME)
Germany
· Delayed Price · Currency is EUR | Market Cap | 13.32B |
| Revenue (ttm) | 19.34B |
| Net Income (ttm) | 537.91M |
| Shares Out | 293.41M |
| EPS (ttm) | 1.83 |
| PE Ratio | 24.81 |
| Forward PE | 12.27 |
| Dividend | 1.44 (3.20%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 439,037 |
| Average Volume | 700,342 |
| Open | 45.41 |
| Previous Close | 45.00 |
| Day's Range | 45.25 - 45.89 |
| 52-Week Range | 32.51 - 48.31 |
| Beta | 0.91 |
| RSI | 53.49 |
| Earnings Date | Feb 25, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial StatementsNews
EQS-DD: Fresenius Medical Care AG: Dr. Katarzyna Mazur-Hofsäß, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:50 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius Medical Care AG: Franklin W. Maddux, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:48 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius Medical Care AG: Helen Pring Giza, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:47 CET/CEST The issuer is solely responsi...
Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum
In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 1...
Fresenius Medical Care AG (FMS) Trading Down 3.52% on Mar 4
Fresenius Medical Care AG (FMS) Trading Down 3.52% on Mar 4
Fresenius Medical Care's stock falls on Fresenius' stake sale
Dialysis firm Fresenius Medical Care shares fell 7.8% after German healthcare group Fresenius SE sold part of its stake in the company.
Fresenius Sells Fresenius Medical Care Stake For $1.15 Billion
The healthcare group said the proceeds will help strengthen its balance sheet and reduce leverage
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Investment Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to...
Fresenius Medical Care AG (FMS) Q4 2024 Earnings Conference Call Transcript
Fresenius Medical Care AG (FMS) Reports Strong Earnings Growth and Strategic Progress in 2024
Fresenius Medical Care AG (FMS) Reports Strong Earnings Growth and Strategic Progress in 2024
Fresenius Medical Care's first ever tariff taskforce looking at potential tariffs on medical equipment, says CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare company's latest earnings and its new tariff task force.
Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025
Organic revenue growth1 of 4% driven by Care Enablement and Care Delivery Underlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full year Accumulated savin...
Fresenius Medical Care AG (FMS) Announces Divestment of Select Laboratory Assets to Quest ...
Fresenius Medical Care AG (FMS) Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Fresenius Medical Care Narrows Key Earnings Metric View on Profit Slump
Fresenius Medical Care slightly beats market estimates in fourth quarter
Fresenius Medical Care , the world's largest dialysis specialist, reported fourth quarter results slightly above market expectations on Tuesday, citing positive development both in its care delivery a...
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J...
Fresenius Medical Care: A 'Buy' Going Into 2025
Fresenius Medical Care has seen 18.5% growth, with strong prospects. Learn why FMS stock’s fair value of $34/share makes it a solid “Buy” opportunity.
Fresenius Medical Care AG (FMS) Recognized for Sustainability Leadership
Fresenius Medical Care AG (FMS) Recognized for Sustainability Leadership
Fresenius Medical Care Listed in The Dow Jones Sustainability World Index and for the 15th Time in The Dow Jones Sustainability Europe Index
Ranking puts Fresenius Medical Care among the best-in-class sustainability performers in the world and Europe The company recorded progress towards its sustainability targets Sustainability is one of ...
Fresenius Medical Care AG (FMS) Rejoins DAX 40 Index
Fresenius Medical Care AG (FMS) Rejoins DAX 40 Index
Fresenius Medical Care returns to Dax 40 Index
BAD HOMBURG, Germany , Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of ...
Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement with Premier, Inc. for the Novalung® ECMO System
Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide. Wide Reach: 4,350+ Premier member hospitals and health systems in ...
Fresenius Medical Care AG (FMS) Stock Price Up 4.03% on Nov 16
Fresenius Medical Care AG (FMS) Stock Price Up 4.03% on Nov 16
‘If they don’t get care, they die’: the woman who runs the world’s largest kidney dialysis company
Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients New popular weight-loss drugs such as Wegovy and Ozempic come with an additional benefit: ...
Hard work paying off despite challenges from U.S. weather-related events: Fresenius Medical Care CEO
Helen Giza, the CEO of Fresenius Medical Care, discusses the German healthcare firm's third-quarter earnings.